Current issue
2 . 2014
Hepatitis B and hepatitis C
Content
Editorial

Editorial

Abstract
News

News

Abstract
Symposium

Outcomes of hepatitis В virus in infectious disease physician practice. Treatment as prevention. Expert's opinions

Abstract
International practice

Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy

Abstract
The profile and clinical significance of serum hepatitis B surface antigen (HBsAg) levels during long-term nucleoside analogue (NA) therapy in chronic hepatitis B (CHB) is undetermined. From 1994 to 2002, 322 Chinese CHB patients were started on lamivudine in our center.

Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy

Abstract
Chronic hepatitis B (CHB) infection is the major cause of hepatocellular carcinoma (HCC). Primary prevention of hepatitis B infection by vaccination is effective in reducing the incidence of HCC. In persons with CHB infection, the two accepted treatment modalities are

Direct-acting antiviral agents and the path to interferon independence

Abstract
Chronic infection with hepatitis C virus (HCV) is a major global health problem; there are approximatel y 120 to 130 million chronic infections worldwide. Since the discovery of HCV 24 years ago, there has been a relentless effort to develop successful antiviral therapies.
Scientific reviews

Hard-to-treat patient with hepatitis C – what will change with interferon-free therapy?

Abstract
The article explores current and future approaches to the management of hard-to-treat patients with chronic HCV infection. Specific features of hard-totreat patients are reviewed in the context of upcoming implementation of IFN-free regimens. Recently published data resulted

Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?

Abstract
The current standard of care (SOC) for patients with chronic HCV genotype 1 is a combination of either boceprevir or telaprevir with peginterferon (PEG-IFN) and ribavirin (RBV). Although it is effective in a high percentage of patients, this treatment is associated with

Protease inhibitors for prophylaxis mother-to-child HIV transmission

Abstract
A substantial part of HIV-infected women are of child-bearing age. This enhances the need for prophylaxis of mother-to-child transmission. According to modern guidelines the most the three-stage approach (during pregnancy, during labor and to the newborn) is most effective.

Detection of LAM-antigen in urine as a rapid method of diacnostics of tuberculosis in HIV-infected patients

Abstract
LAM-ELISA is a new method of laboratory diagnostics of tuberculosis in HIV-positive patients based on detection of the cell wall lipoarabinomannan of Mycobacterium sp. in urine. The test sensitivity increases with decreasing number of CD4 + -lymphocytes and peaks at 50
Original articles

Elastometry in complex assessment of hepatic fibrosis in patients with HIV and HIV/VHC coinfected patients

Abstract
314 HIV-infected patients were examined in this trial including 281 patients with HIV/HCV co-infection an d 33 patients with HIV mono-infection. Anti-HCV therapy and HAART (Highly Active Antiretroviral Therapy) wasn`t prescribed to the all patients earlier. Fibrosis was

Pharmacoeconomic aspects of HIV therapy with the use of highly active anti-retroviral therapy fixed dose combination (emtricitabine/rilpivirine/ tenofovir)

Abstract
Fixed-doze combination of rilpivirine, tenofovir andemtricitabine in highly active antiretroviral therapy makes possible to decrease costs comparing to combinations of rilpivirine with fixed doze tenofovir/emtricitabine and raltegravir with fixed doze tenofovir/emtricitabine
Clinical tests

Clinical cases

Abstract

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

CHIEF EDITOR
Aleksandr V. Gorelov
Academician of the Russian Academy of Sciences, MD, Head of Infection Diseases and Epidemiology Department of the Scientific and Educational Institute of Clinical Medicine named after N.A. Semashko ofRussian University of Medicine, Ministry of Health of the Russian Federation, Professor of the Department of Childhood Diseases, Clinical Institute of Children's Health named after N.F. Filatov, Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation, Deputy Director for Research, Central Research Institute of Epidemiology, Rospotrebnadzor (Moscow, Russian Federation)

Journals of «GEOTAR-Media»